New collaboration between leadXpro and Orbion!

Membrane proteins serve as a cell’s vital link to its external environment and play crucial roles in both health and disease. Although they make up only about a quarter of the human proteome, they are the targets of more than half of all approved drugs. However, studying these proteins in the lab is challenging due to their inherent instability and typically low levels of expression.

To confront this problem, we collaborate with Orbion. Orbion has a new Astra AI model that can further enhance our membrane protein platform. This partnership highlights Orbion’s dedication to delivering practical, valuable guidance for protein research and leadXpro’s commitment to integrating machine learning into its technology platform. We believe the collaboration will strengthen our protein engineering platform and improve the quality of membrane protein we produce, thus greatly accelerate our research programs.

leadXpro’s comment:

Membrane proteins remain some of the hardest drug targets to study. Producing high-quality proteins for biophysics and structure research is our passion and mission. We further enhance our technology platform by merging our existing expertise with Orbion’s machine learning pipeline in protein science and seek to leverage the combined expertise to accelerate drug discovery research and unlock tomorrow’s medicine.

Orbion’s comment:

When a challenge touches billions of lives, the stakes skyrocket. Membrane proteins are just that: barely 10% are drugged because of their volatility. At Orbion, hard never means impossible – it just takes the right people and partners. By joining leadXpro’s structural biology brilliance with our predictive machine learning pipeline, we’ll bring clarity to membrane proteins and unlock next generation drugs for today’s unknown diseases.